NCT02774681View on ClinicalTrials.gov

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

February 13, 2019

Study Completion Date

February 16, 2020

Conditions
Breast Carcinoma Metastatic in the BrainEstrogen Receptor NegativeHER2/Neu NegativeHER2/Neu PositiveProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast Cancer
Interventions
PROCEDURE

Cognitive Assessment

Ancillary studies

DRUG

Palbociclib

Given PO

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (3)

60045

Northwestern Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

77030

Houston Methodist Hospital/Houston Methodist Cancer Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT02774681 - Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | Biotech Hunter | Biotech Hunter